(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The Development of Shipping: Controlling Towards a More Associated Future - 2Tesla Germany Registrations Quadruple to 9,252 Vehicles in Best March Ever
- 3Novo Nordisk slashes prices of popular weight loss and diabetes drugs
- 4RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
- 5Virtual reality opens doors for older people to build closer connections in real life
- Pick Your Favored kind of books
- Map shows more than 1,900 measles cases across U.S.
- Four Dead in Last Month From Animal Attacks in Nepal
- Manual for Picking Coastline Travel
- Savvy Tips for Seniors Hyundai IONIQ EV
- 21 Things You Ought to Never Share with Your Childless Companion
- Astronomers discover never-before-seen celestial object: "Cloud 9"
- Telecommute Arrangement: What's Pivotal for Your Efficiency?
- Iranian-linked drone attack kills Kurdish couple in northern Iraq
